Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05626920 · ClinicalTrials.gov registry record · Phase 1
Disulfiram for Treatment of Retinal Degeneration
A Phase 1 study of Inherited Retinal Dystrophy Primarily Involving Sensory Retina, sponsored by University of Washington.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05626920: Recruiting Phase 1 study of Inherited Retinal Dystrophy Primarily Involving Sensory Retina, sponsored by University of Washington.
NCT05626920 is a Phase 1 study of Inherited Retinal Dystrophy Primarily Involving Sensory Retina that is actively recruiting participants, run by University of Washington. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05626920, a Phase 1 study of Inherited Retinal Dystrophy Primarily Involving Sensory Retina, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Aberrant retinoic acid signaling driven by the degenerating outer retina leads to pathological changes to the inner retina. The resulting hyperactivity of retinal ganglion cells leads to further diminution of the remaining vision in those afflicted with inherited retinal diseases. Inhibition of this pathway has led to improved visual function in murine models of retinal degeneration. This can be accomplished in humans with the FDA-approved irreversible inhibitor of aldehyde dehydrogenases, disulfiram.
Primary Outcome
Evaluate change in contrast sensitivity measured by spatial contrast contrast sensitivity testing between disulfiram and placebo arms
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Disulfiram 250 mg
Study Locations (1)
Washington
- University of Washington-South Lake Union Retina Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-01-03 |
| Est. Completion | 2025-11-01 |
| Phase | Phase 1 |
What NCT05626920 shows while recruiting
NCT05626920 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Inherited Retinal Dystrophy Primarily Involving Sensory Retina appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05626920 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT05626920 about?
NCT05626920 is a clinical study titled "Disulfiram for Treatment of Retinal Degeneration". Aberrant retinoic acid signaling driven by the degenerating outer retina leads to pathological changes to the inner retina. The resulting hyperactivity of retinal ganglion cells leads to further diminution of the remaining vision in those afflicted with inherited retinal diseases. Inhibition of this...
What is the current status of trial NCT05626920?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-01-03. Estimated completion is 2025-11-01.
What conditions does trial NCT05626920 study?
This clinical trial studies the following conditions: Inherited Retinal Dystrophy Primarily Involving Sensory Retina.
What interventions are being tested in trial NCT05626920?
The interventions under investigation include: Placebo (DRUG), Disulfiram 250 mg (DRUG).
Who is sponsoring clinical trial NCT05626920?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05626920 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05626920's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI